Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Accounts Payables (2016 - 2026)

Apyx Medical filings provide 16 years of Accounts Payables readings, the most recent being $3.1 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 16.94% to $3.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.1 million, a 16.94% increase, with the full-year FY2025 number at $3.1 million, up 16.94% from a year prior.
  • Accounts Payables hit $3.1 million in Q4 2025 for Apyx Medical, down from $3.2 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $3.2 million in Q3 2025 to a low of $1.9 million in Q1 2023.
  • Median Accounts Payables over the past 5 years was $2.6 million (2022), compared with a mean of $2.5 million.
  • Biggest five-year swings in Accounts Payables: soared 74.12% in 2021 and later crashed 32.0% in 2022.
  • Apyx Medical's Accounts Payables stood at $2.6 million in 2021, then increased by 1.44% to $2.7 million in 2022, then increased by 1.61% to $2.7 million in 2023, then dropped by 3.58% to $2.6 million in 2024, then grew by 16.94% to $3.1 million in 2025.
  • The last three reported values for Accounts Payables were $3.1 million (Q4 2025), $3.2 million (Q3 2025), and $2.9 million (Q2 2025) per Business Quant data.